RR&D Research Career Scientist Award Application

帕杜博士的研究计划集中在为患有以下疾病的退伍军人开发改变生活的疗法 视力丧失。她在三个研究领域做出了重大贡献：a)视网膜治疗 变性，b)糖尿病视网膜病变的早期发现和治疗，c)屈光不正的视网膜机制 发展。她的研究项目的临床前研究加深了我们对 致盲疾病的基础机制和先进的新治疗选择。她的双重身份是 退伍军人管理局和佐治亚理工学院创造了一种独特的情况，可以利用资源和协作来推动 将技术应用于临床。她坚信，合作研究对成果的转化至关重要 从长凳到床边。这一点反映在她的89种出版物中，超过75%的出版物源于与 超过46名不同的调查人员。此外，她的发现也为翻译研究的三个领域奠定了基础 对人类患者(视网膜假体、糖尿病视网膜病变和神经保护疗法)。帕杜博士二重奏 任命和研究兴趣创造了新的机会，可以在 具有开创性发现潜力的不同系统和研究领域。 帕杜博士对教学和指导的承诺体现在几个角色上。她有 在过去的18年里向本科生和研究生讲授视网膜和视觉系统 担任过7门课程的讲师。帕杜博士对专业发展有着浓厚的兴趣， 为退伍军人管理局、埃默里大学和佐治亚州的博士后和研究生组织并讲授有关这一主题的课程 技术，以及在国际会议上。此外，她还积极支持科学领域的女性 通过机构和国际课程的研究生和初级教员水平。帕杜博士指导了5位 退伍军人管理局职业发展奖(CDA)。她指导过的学生中有80%以上继续 在医学或科学领域。 帕杜博士在她的整个职业生涯中一直服务于科学界。具体到退伍军人管理局， 帕杜博士在2004年至2008年担任IACUC委员会主席，并在过去十年担任研发委员会主席 年份(2008年至今)。她协助亚特兰大退伍军人康复中心成功地完成了两个续签周期。作为 科学项目副主任，她领导了所有康复中心的内部审查过程 提交意见书，将资助率提高至20%(功绩)和42%(综合评议会)。她目前担任 越南船级社临时副主任。她也是亚特兰大退伍军人事务部非营利性组织顾问委员会的成员 基础(Aref)。在国际层面上，她曾在阿尔沃的几个委员会任职，并被 在2016年5月获得了他们享有盛誉的银质伙伴奖。帕杜博士曾在多个研究部门任职。 来自美国国立卫生研究院、弗吉尼亚州以及各种国家和国际私人基金会。她目前是一名常客 美国国立卫生研究院神经科学和眼科成像技术(NOIT)研究组成员。她的贡献 该领域的领导地位在2017年通过入职美国研究所获得认可 医学和生物工程师(AIMBE)。 帕杜博士未来的目标是1)开发新的失明疾病康复策略，2)确定 糖尿病视网膜病变的最早迹象，并确定早期干预措施以减缓视力进展 3)确定多巴胺在屈光性眼睛生长中的作用。这些目标是以结果为基础的 在过去的几年里，她的实验室取得了很大的进步，包括出版了越来越多的高影响力出版物 日记。在先前成功的基础上，她预测新的治疗策略的发展。翻译： 这些发现从实验室到临床将由她在CVNR和CVNR内部的合作促进 退伍军人管理局的临床医生。因此，这些项目既支持理解和治疗视网膜的共同主题 疾病以延长功能视力和退伍军人管理局改善退伍军人医疗保健的使命。

Dr. Pardue’s research program is centered on developing life-changing treatments for veterans with vision loss. She has made significant contributions in three research areas: a) treatments for retinal degeneration, b) early detection and treatment of diabetic retinopathy, and c) retinal mechanisms of refractive development. Pre-clinical studies from her research program have enhanced our understanding of mechanisms that underlie blinding diseases and advanced new treatment options. Her dual position between the VA and Georgia Tech creates a unique situation to leverage resources and collaborations to move new technologies into the clinic. She is a firm believer that collaborative research is essential to translate results from bench to bedside. This is reflected in over 75% of her 89 publications stemming from collaborations with over 46 different investigators. Moreover, her findings have formed the basis for 3 areas of translational studies to human patients (retinal prosthetics, diabetic retinopathy, and neuroprotection therapies). Dr. Pardue’s dual appointment and research interests create novel opportunities to draw parallels and intersections between different systems and fields of study with the potential for ground-breaking discoveries. Dr. Pardue’s commitment to teaching and mentorship are illustrated by a number of roles. She has lectured to undergraduate and graduate students on the retina and visual system for the last 18 years and been the instructor for 7 courses. Dr. Pardue has a strong interest in professional development and has organized and taught courses for post-docs and graduate students on this topic at the VA, Emory, and Georgia Tech, as well as at international conferences. In addition, she actively supports women in science at the graduate and junior faculty levels through institutional and international programs. Dr. Pardue has mentored 5 VA Career Development Awardees (CDAs). Over 80% of the students that she has mentored have continued on in medicine or science. Dr. Pardue has consistently served the scientific community throughout her career. Specific to the VA, Dr. Pardue chaired the IACUC Committee from 2004-2008 and has chaired the R&D Committee for the last ten years (2008-date). She assisted with two successful renewal cycles of the Atlanta VA Rehab Center. As the Associate Director of Scientific Projects, she directed the internal review process of all Rehab Center submissions, increasing the funding rate to 20% for Merits and 42% for CDAs. She currently serves as the interim Associate Director of the CVNR. She also serves on the Advisory Board for the Atlanta VA non-profit foundation (AREF). On the international level, she has served on several committees for ARVO and was awarded their prestigious Silver Fellow Award in May 2016. Dr. Pardue has served on many study sections from NIH, VA, and various national and international private foundations. She currently serves as a regular member of NIH Neuroscience and Ophthalmic Imaging Technologies (NOIT) study section. Her contributions and leadership in the field was recognized in 2017 by induction as a fellow into the American Institute of Medical and Biological Engineers (AIMBE). Dr. Pardue’s future goals are to 1) develop new rehabilitation strategies for blinding diseases, 2) identify the earliest signs of diabetic retinopathy and determine early interventions to slow the progression of vision loss, and 3) determine the role of dopamine in refractive eye growth. These goals are grounded in the results from her laboratory over the last several years, including the increased number of publications in high impact journals. Based on prior success, she anticipates the development of new treatment strategies. Translation of these findings from the laboratory to the clinic will be facilitated by her collaborations within the CVNR and clinicians at the VA. Thus, these projects support both the common theme of understanding and treating retinal disease to prolong functional vision and the VA mission of improving healthcare for veterans.